OVIDHealthcare · BiotechnologyOVID Stock Forecast: Ovid Therapeutics, Inc. Price Predictions for 2026-2027
The 10 Wall Street analysts covering Ovid Therapeutics, Inc. hold a median 12-month price target of $5 — +114.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 1 Aug 2026 — in the upper half.
OVID stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Ovid Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Accruals (19): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
The rank is the raw material. Whether the rules would actually own Ovid Therapeutics, Inc. — and when they’d sell — is the membership.
OVID stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OVID, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +114.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 Apr 2026 | Wedbush | Reiterates | Outperform | $7.00 |
| 9 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | $2.00 → $4.00 |
| 26 Mar 2026 | BTIG | Reiterates | Buy | — |
| 20 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 22 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Dec 2025 | LifeSci Capital | Initiates | Outperform | — |
| 11 Dec 2025 | Roth Capital | Initiates | Buy | — |
| 24 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Nov 2025 | Leerink Partners | Initiates | Outperform | — |
| 27 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Mar 2025 | BTIG | Maintains | Buy | — |
| 24 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Mar 2025 | Wedbush | Maintains | Outperform | — |
| 29 Jan 2025 | Oppenheimer | Upgrade | Outperform | — |
| 4 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 June 2024 | B. Riley Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OVID analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Ovid Therapeutics, Inc. (OVID) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −9.6×
- Price / sales
- 58.2×
- Price / book
- 1.9×
- EV / EBITDA
- −5.6×
Cheaper than 92% of US stocks
Cheaper than 5% of US stocks
Cheaper than 48% of US stocks
Cheaper than 80% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- −100.0%
- Gross margin
- —
- Operating margin
- −678.7%
- Net margin
- 0.0%
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 7% of US stocks
Higher than 30% of US stocks
- Return on equity
- −18.8%
- Return on assets
- −19.7%
- Dividend yield
- —
Higher than 31% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
OVID vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OVID appears on the weeks it earns a place.
Frequently asked questions about OVID stock
What is the OVID stock price forecast for 2026-2027?
The 10 Wall Street analysts covering Ovid Therapeutics, Inc. have a median 12-month price target of $5, with estimates ranging from $4 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is OVID stock a buy right now?
Of the 10 analysts covering Ovid Therapeutics, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ovid Therapeutics, Inc. 64 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank OVID?
As at 1 Aug 2026, Ovid Therapeutics, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
Will OVID stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts implies +114.6% from the last close, and Ticker Nerd's factor model ranks Ovid Therapeutics, Inc. 64 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the OVID stock forecast for 2030?
No analyst covering Ovid Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OVID are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $7 over the next 12 months.
How has OVID stock performed over the past year?
Ovid Therapeutics, Inc. returned +366.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Ovid Therapeutics, Inc. do?
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain conditions characterized by excess neural excitability, such as rare neurological disorders, epilepsies, and seizure-related issues.
About Ovid Therapeutics, Inc.
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain conditions characterized by excess neural excitability, such as rare neurological disorders, epilepsies, and seizure-related issues. The company advances a pipeline targeting neuronal hyperexcitability to restore excitatory-inhibitory balance in the brain. Key programs include OV329, a next-generation GABA-aminotransferase inhibitor designed to increase GABA levels for treatment-resistant seizures with potentially improved safety over prior drugs, currently in Phase 1 clinical trials. Ovid Therapeutics also develops a portfolio of KCC2 direct activators, including OV350 as an intravenous tool compound evaluated in Phase 1 for foundational safety data, and OV4071, an oral candidate prioritized for neuropsychiatric conditions like psychosis in Parkinson's disease and Lewy body dementia. Additional compounds from its proprietary KCC2 library support oral and injectable formulations for neurological, neurodevelopmental, and neurodegenerative applications. Founded in 2014 and headquartered in New York, Ovid Therapeutics concentrates on biomarker-driven development for central nervous system disorders with significant unmet needs.
CEO Ms. Margaret Alexander · 23 employees · United States · https://www.ovidrx.com